Log in

NASDAQ:LIVNLivaNova Stock Price, Forecast & News

$47.49
+0.43 (+0.91 %)
(As of 08/7/2020 04:00 PM ET)
Add
Compare
Today's Range
$46.69
Now: $47.49
$48.33
50-Day Range
$45.75
MA: $51.12
$57.81
52-Week Range
$33.40
Now: $47.49
$87.45
Volume289,358 shs
Average Volume587,196 shs
Market Capitalization$2.31 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.81
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV”) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients. It also provides surgical tissue and mechanical valve replacements, and repair products for damaged or diseased heart valves, such as self-anchoring tissue heart, tissue heart, and mechanical heart valves, as well as heart valve repair products; and temporary extracorporeal cardiopulmonary life support solutions for critically ill patients. The NM segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, treatment-resistant depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company was founded in 1987 and is headquartered in London, the United Kingdom.
Read More
LivaNova logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.41 out of 5 stars


Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:LIVN
CUSIPN/A
Phone44-0-20-3325-0660

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.08 billion
Cash Flow$5.76 per share
Book Value$27.39 per share

Profitability

Net Income$-155,180,000.00

Miscellaneous

Employees4,000
Market Cap$2.31 billion
Next Earnings Date11/4/2020 (Estimated)
OptionableOptionable
$47.49
+0.43 (+0.91 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive LIVN News and Ratings via Email

Sign-up to receive the latest news and ratings for LIVN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











LivaNova (NASDAQ:LIVN) Frequently Asked Questions

How has LivaNova's stock been impacted by COVID-19 (Coronavirus)?

LivaNova's stock was trading at $62.65 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, LIVN stock has decreased by 24.2% and is now trading at $47.49.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of LivaNova?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for LivaNova in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for LivaNova
.

When is LivaNova's next earnings date?

LivaNova is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for LivaNova
.

How were LivaNova's earnings last quarter?

LivaNova PLC (NASDAQ:LIVN) issued its quarterly earnings results on Wednesday, July, 29th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.30) by $0.15. The business had revenue of $182.20 million for the quarter, compared to the consensus estimate of $169.74 million. LivaNova had a positive return on equity of 7.00% and a negative net margin of 16.47%. The firm's quarterly revenue was down 34.3% on a year-over-year basis. During the same quarter last year, the company earned $0.70 earnings per share.
View LivaNova's earnings history
.

What guidance has LivaNova issued on next quarter's earnings?

LivaNova issued an update on its FY20 earnings guidance on Wednesday, July, 29th. The company provided earnings per share guidance of $1.15-1.35 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.47. The company issued revenue guidance of decline 7-17% yr/yr to $900 million to $1.01 billion, compared to the consensus revenue estimate of $937.94 million.

What price target have analysts set for LIVN?

7 equities research analysts have issued twelve-month price targets for LivaNova's shares. Their forecasts range from $40.00 to $114.00. On average, they anticipate LivaNova's stock price to reach $68.43 in the next twelve months. This suggests a possible upside of 44.1% from the stock's current price.
View analysts' price targets for LivaNova
.

Has LivaNova been receiving favorable news coverage?

News coverage about LIVN stock has been trending very positive recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. LivaNova earned a news impact score of 4.0 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days.
View the latest news about LivaNova
.

Who are some of LivaNova's key competitors?

What other stocks do shareholders of LivaNova own?

Who are LivaNova's key executives?

LivaNova's management team includes the following people:
  • Mr. Damien McDonald, CEO & Director (Age 54)
  • Mr. Thad Huston, Chief Financial Officer (Age 49)
  • Mr. Douglas J. Manko, Chief Accounting Officer (Age 45)
  • Ms. Keyna Pidcock Skeffington, Gen. Counsel & Sr. VP (Age 56)
  • Mr. David S. Wise, Sr. Advisor (Age 64)

What is LivaNova's stock symbol?

LivaNova trades on the NASDAQ under the ticker symbol "LIVN."

Who are LivaNova's major shareholders?

LivaNova's stock is owned by many different institutional and retail investors. Top institutional shareholders include Paradice Investment Management LLC (1.72%), KEYWISE CAPITAL MANAGEMENT HK Ltd (0.85%), Hosking Partners LLP (0.53%), Emerald Advisers LLC (0.45%), Rhenman & Partners Asset Management AB (0.45%) and Emerald Mutual Fund Advisers Trust (0.43%). Company insiders that own LivaNova stock include Alfred J Novak, Alistair Simpson, Damien Mcdonald, Daniel Jeffrey Moore, David S Wise, Douglas John Manko, Hugh M Morrison, Thad Allen Huston and William A Kozy.
View institutional ownership trends for LivaNova
.

Which institutional investors are selling LivaNova stock?

LIVN stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, Hosking Partners LLP, Strs Ohio, Paradice Investment Management LLC, CWM LLC, SG Americas Securities LLC, Community Capital Management Inc., and Texas Permanent School Fund. Company insiders that have sold LivaNova company stock in the last year include Damien Mcdonald, Daniel Jeffrey Moore, and Thad Allen Huston.
View insider buying and selling activity for LivaNova
.

Which institutional investors are buying LivaNova stock?

LIVN stock was acquired by a variety of institutional investors in the last quarter, including KEYWISE CAPITAL MANAGEMENT HK Ltd, Platinum Investment Management Ltd., Sycomore Asset Management, Rhenman & Partners Asset Management AB, Wedge Capital Management L L P NC, PNC Financial Services Group Inc., Russell Investments Group Ltd., and Emerald Mutual Fund Advisers Trust. Company insiders that have bought LivaNova stock in the last two years include Alfred J Novak, and William A Kozy.
View insider buying and selling activity for LivaNova
.

How do I buy shares of LivaNova?

Shares of LIVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is LivaNova's stock price today?

One share of LIVN stock can currently be purchased for approximately $47.49.

How big of a company is LivaNova?

LivaNova has a market capitalization of $2.31 billion and generates $1.08 billion in revenue each year. The company earns $-155,180,000.00 in net income (profit) each year or $3.08 on an earnings per share basis. LivaNova employs 4,000 workers across the globe.

What is LivaNova's official website?

The official website for LivaNova is www.livanova.com.

How can I contact LivaNova?

LivaNova's mailing address is 20 EASTBOURNE TERRACE, LONDON X0, W2 6LG. The company can be reached via phone at 44-0-20-3325-0660 or via email at [email protected]

This page was last updated on 8/8/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.